Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”

অনুরূপ উপাদানগুলি

• Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose—the PP100–01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial
  অনুযায়ী: Dear, James
  প্রকাশিত: (2019)
• Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)
  অনুযায়ী: Morrison, Emma E., অন্যান্য
  প্রকাশিত: (2019)
• Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir?
  অনুযায়ী: Karlsson, Jan Olof G.
  প্রকাশিত: (2019)
• Novel acetylcysteine regimens for treatment of paracetamol overdose
  অনুযায়ী: Waring, W. Stephen
  প্রকাশিত: (2012)
• Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose
  অনুযায়ী: Pettie, Janice M., অন্যান্য
  প্রকাশিত: (2019)